A5055766851- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Surgical Treatments
- Radiomics and Machine Learning in Medical Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Renal cell carcinoma treatment
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Cancer Cells and Metastasis
- Medical Imaging Techniques and Applications
- Multiple and Secondary Primary Cancers
- Pancreatitis Pathology and Treatment
- Colorectal Cancer Screening and Detection
- Peptidase Inhibition and Analysis
- Gastrointestinal Tumor Research and Treatment
Charité - Universitätsmedizin Berlin
2020-2025
Humboldt-Universität zu Berlin
2020-2025
Freie Universität Berlin
2021-2025
German Cancer Research Center
2015-2024
Heidelberg University
2015-2024
Deutschen Konsortium für Translationale Krebsforschung
2017-2024
German Cancer Society
2022-2024
University of Southampton
2023
Southampton General Hospital
2023
Ludwig-Maximilians-Universität München
2013-2022
To explore the impact of KRAS, NRAS and BRAF mutations as well KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy.A total 1239 from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into analysis. Outcome was evaluated by Kaplan-Meier method, log-rank tests Cox models.In 664 tumors, no detected, 462 tumors diagnosed KRAS-, 39 NRAS- 74 BRAF-mutation. Mutations associated inferior progression-free survival...
In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients metastatic colorectal cancer. Preliminary data from single-group and randomized 2 trials suggest that FTD-TPI in addition to bevacizumab has the potential extend survival.We randomly assigned, 1:1 ratio, adult who had received no more than two chemotherapy regimens for of advanced cancer receive plus (combination group) or alone (FTD-TPI group). The primary end point was...
BackgroundFIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to their gene-signature four different subtypes. Relevance of CMS for the treatment mCRC has yet be defined.Patients and MethodsIn this exploratory analysis, patients were grouped previously published tumor CRC-CMSs. Objective response rates (ORR)...
This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, open-label, phase II patients untreated RAS wild-type (WT) metastatic colorectal cancer.The primary end point was objective response rate (ORR) according RECIST (version 1.1). The experimental arm (modified FOLFOXIRI [mFOLFOXIRI] plus panitumumab) considered active if ORR ≥ 75%. compared an estimated 60%...
G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy KRAS inhibitors has yielded only modest efficacy. Combining the inhibitor sotorasib panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be effective strategy.
Up to now, the efficacy of programmed death protein 1/programmed ligand 1 (PD-1/PD-L1) blockade in pancreatic cancer (PC) remains uncertain. Serum levels soluble PD-1 and PD-L1 (sPD-1/sPD-L1) have been reported be independent prognostic factors solid tumors susceptible checkpoint blockade. Provenience, regulation immunologic function sPD-1 sPD-L1 are poorly understood. To best our knowledge, not measured conjointly any type yet. In contrast other tumor entities, sPD-1/sPD-L1 did indicate an...
Perioperative treatment is a standard of care in locally advanced gastroesophageal cancer (GEC) (gastric adenocarcinoma and junction (GEJ) adenocarcinoma). While preoperative can be applied to the majority patients, postoperative chemotherapy given only fraction. The NeoFLOT-study therefore investigates application prolonged neoadjuvant (NACT). Patients with T3, T4, and/or node-positive were eligible for this multicenter phase II trial. NACT consisted 6 cycles oxaliplatin 85 mg/m(2) ,...
Purpose We investigated choice and efficacy of subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus cetuximab [arm A] or bevacizumab B]) for patients KRAS wild-type metastatic colorectal cancer. Patients Methods Start subsequent-line (second third) therapy was defined as use an antitumor drug that not part previous regimen. evaluated choice, duration, determined impact treatment outcome FIRE-3. Results Of 592 intent-to-treat population, 414...
Abstract Background Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab in KRAS wild-type metastatic colorectal cancer (mCRC) FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis aimed to determine whether cetuximab improves response and versus among response-evaluable patients receiving first-line RAS mCRC the effect of primary tumour side on outcomes. Methods The intent-to-treat population included 593 exon 2 mCRC. Further...
AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus oxaliplatin. This analysis the impact primary tumor location on outcome patients. Left-sided tumors were defined as from rectum to left flexure, while in remaining colon regarded right sided. Overall survival (OS), progression-free (PFS) response rate correlated location. A Cox regression model was used evaluate interaction between KRAS mutation. Of 146...
445 Background: The FIRE-3 study (AIO KRK-0306) was designed as a randomized multicenter trial to compare the efficacy of FOLFIRI plus cetuximab (cet) bevacizumab (bev) first-line treatment in KRAS WT mCRC patients. cet patients resulted comparable overall response rates (ORR) and progression free survival (PFS) when compared bev. Overall (OS) significantly longer arm. Methods: In preplanned analysis, effect mutations within EGFR dependent pathway were investigated. Next (exon 2, 3, 4), NRAS...
4 Background: Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (Bev) demonstrated promising efficacy in a randomized phase 2 trial of heavily pretreated patients (pts) with metastatic colorectal cancer (mCRC). SUNLIGHT was conducted to confirm these findings. Methods: The global 3 study enrolled pts aged ≥18 years histologically confirmed mCRC, ECOG PS 0/1, and treated 1-2 prior chemotherapy regimens an advanced setting, including fluoropyrimidines, irinotecan, oxaliplatin, anti-VEGF...
BRAFV600E mutation is associated with a poor outcome in metastatic colorectal cancer (mCRC). This clinical trial investigated the efficacy of triplet chemotherapy (fluorouracil, folinic acid, oxaliplatin, and irinotecan) combined either cetuximab or bevacizumab patients previously untreated BRAFV600E-mutant mCRC.In this controlled, randomized, open-label phase II trial, 109 were randomly assigned, 107 whom included into full analysis set (FAS). Patients assigned 2:1 ratio to receive...
LBA3506 The full, final text of this abstract will be available at abstract.asco.org 7:30 AM (EDT) on Saturday June, 1, 2013, and in the Annual Meeting Proceedings online supplement to June 20, issue Journal Clinical Oncology. Onsite Meeting, printed edition ASCO Daily News.
Abstract Skin toxicity is a frequent adverse event of epidermal growth factor receptor (EGFR) targeting agents. Occurrence cetuximab‐induced skin (Cet‐ST) correlates with better treatment response and longer survival times. Molecular markers predicting Cet‐ST are still missing. This investigation analyzed the value for efficacy in randomized trial comparing cetuximab plus capecitabine/irinotecan to capecitabine/oxaliplatin as first‐line metastatic colorectal cancer. Patient characteristics...